Skip to main content
SpringerLink
Log in

How should clinical data be included in experimental studies of cancer immunology?

  • Opinion Paper
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Patients diagnosed with the same malignant disease are often heterogeneous with regard to age, complications, malignant cell morphology and tumor histology, disease stage, prognostic parameters, and previous therapy. Many of these factors can affect immunocompetent cells or influence the malignant cell susceptibility to immunotherapy. Summaries of relevant clinical information should therefore be included in cancer immunology studies to increase the present as well as the future scientific impact. Guidelines for selection of relevant information are suggested in the article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barber MD, Ross JA, Fearon KC (1999) Cancer cachexia. Surg Oncol 8:133

    Article  CAS  PubMed  Google Scholar 

  2. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T (2003) p53 Polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387

    CAS  PubMed  Google Scholar 

  3. Bladergroen BA, Meijer CJ, ten Berge RL, Hack CE, Muris JJ, Dukers DF, Chott A, Kazama Y, Oudejans JJ, van Berkum O, Kummer JA (2002) Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 99:232

    Article  CAS  PubMed  Google Scholar 

  4. Bruserud Ø, Hovland R, Wergeland L, Huang T-S, Gjertsen BT (2003) Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of the effects of Flt3-ligand in AML cell populations with and without Flt3 abnormalities. Haematologica 88:416

    CAS  PubMed  Google Scholar 

  5. Clark PE, Irvine RA, Coetzee GA (2003) The androgen receptor CAG repeat and prostate cancer risk. Methods Mol Med 81:255

    Article  CAS  PubMed  Google Scholar 

  6. Crocker IP, Lawson N, Baker PN, Fletcher J (2001) The anti-inflammatory effects of circulating fatty acids in obstructive jaundice: similarities with pregnancy-induced immunosuppression. QJM 94:475

    Google Scholar 

  7. Dreger P, Viehmann K, von Neuhoff N, Glaubitz T, Petzoldt O, Glass B, Uharek L, Rautenberg P, Suttorp M, Mills B, Mitsky P, Schmitz N (1999) Autografting of highly purified blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery. Bone Marrow Transplant 24:153

    Article  CAS  PubMed  Google Scholar 

  8. Kalil N, Cheson BD (1999) Chronic lymphocytic leukemia. Oncologist 4:352

    CAS  PubMed  Google Scholar 

  9. Lazarus R, Vercelli D, Palmer LJ, Klimecki WJ, Silverman EK, Richter B, Riva A, Ramoni M, Martinez FD, Weiss ST, Kwiatkowski DJ (2002) Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease. Immunol Rev 190:9.

    Article  CAS  PubMed  Google Scholar 

  10. Lieubeau B, Heymann MF, Henry F, Barbieux I, Meflah K, Gregoire M (1999) Immunomodulatory effects of tumor-associated fibroblasts in colorectal-tumor development. Int J Cancer 81:629

    Article  CAS  PubMed  Google Scholar 

  11. Lillie EO, Bernstein L, Ursin G (2003) The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer. Breast Cancer Res 5:164

    Article  PubMed  Google Scholar 

  12. Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, Wexler LH, Adde MA, McClure LL, Gress RE (1994) Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 84:2221

    PubMed  Google Scholar 

  13. Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, Horowitz ME, Magrath IT, Shad AT, Steinberg SM. (1995) Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 332:143

    Article  PubMed  Google Scholar 

  14. Mackall CL, Fleischer TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, Magrath IT, Wexler LH, Dimitrov DS, Gress RE (1997) Distinctions between CD8+ and CD4+ T cell regenerative pathways result in prolonged T cell subset imbalance after intensive chemotherapy. Blood 89:3700.

    CAS  PubMed  Google Scholar 

  15. Mackall CL, Stein D, Fleisher TA, Brown MR, Hakim FT, Bare CV, Leitman SF, Read EJ, Carter CS, Wexler LH, Gress RE (2000) Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood 96:754

    CAS  PubMed  Google Scholar 

  16. McCarthy LC, Davies KJ, Campbell DA (2002) Pharmacogenetics in diverse ethnic populations--implications for drug discovery and development. Pharmacogenomics 3:493

    CAS  PubMed  Google Scholar 

  17. Molloy EJ, O’Neill AJ, Grantham JJ, Sheridan-Pereira M, Fitzpatrick JM, Webb DW, Watson RW (2003) Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood 102:2653

    Article  CAS  PubMed  Google Scholar 

  18. Oppenheimer SJ (2001) Iron and its relation to immunity and infectious diseases. J Nutr 131:616S

    CAS  PubMed  Google Scholar 

  19. Pawelec G, Barnett Y, Forsey R, Frasca D, Globerson A, McLeod J, Caruso C, Franceschi C, Fulop T, Gupta S, Mariani E, Mocchegiani E, Solana R (2002) T cells and aging, January 2002 update. Front Biosci 7:1056

    CAS  PubMed  Google Scholar 

  20. Pedersen BK, Toft AD (2000) Effects of exercise on lymphocytes and cytokines. Br J Sports Med 34:246

    Article  CAS  PubMed  Google Scholar 

  21. Schroder J, Kahlke V, Staubach KH, Zabel P, Stuber F (1998) Gender differences in human sepsis. Arch Surg 133:1200

    PubMed  Google Scholar 

  22. Shresta S, Pham CT, Thomas DA, Graubert TA, Ley TJ (1998) How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 10:581

    CAS  PubMed  Google Scholar 

  23. Talmadge JE, Reed EC, Kessinger A, Kuszynski CA, Perry GA, Gordy CL, Mills KC, Thomas ML, Pirruccello SJ, Letheby BA, Arneson MA, Jackson JD (1996) Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 17:101

    CAS  PubMed  Google Scholar 

  24. Talmadge JE, Reed E, Ino K, Kessinger A, Kuszynski C, Heimann D, Varney M, Jackson J, Vose JM, Bierman PJ (1997) Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant 19:161

    CAS  PubMed  Google Scholar 

  25. Ungefroren H, Kruse ML, Trauzold A, Roeschmann S, Roeder C, Arlt A, Henne-Bruns D, Kalthoff H (2001) FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis. J Cell Sci 114:2735

    CAS  PubMed  Google Scholar 

  26. Vos M, Adams CH, Victor TC, van Helden PD (2003) Polymorphisms and mutations found in the regions flanking exons 5 to 8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa. Cancer Genet Cytogenet 140:23

    Article  CAS  PubMed  Google Scholar 

  27. Wendelbo Ø, Nesthus I, Sjo M, Ernst P, Bruserud Ø (2004) Cellular immune responses in multiple myeloma patients with treatment-induced cytopenia early after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Leukemia Res (in press)

  28. Wendelbo Ø, Nesthus I, Sjo M, Paulsen K, Ernst P, Bruserud Ø (2004) Functional characterization of T Lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia. Cancer Immunol Immunother 53 (DOI 10.1007/s00262-004-0505-0)

Download references

Acknowledgements

The study was supported by the Norwegian Cancer Society.

Author information

Authors and Affiliations

  1. Section for Hematology, Department of Medicine and Institute of Medicine, Haukeland University Hospital, N-5021, Bergen, Norway

    Bjørn Tore Gjertsen & Øystein Bruserud

  2. University of Bergen, Bergen, Norway

    Bjørn Tore Gjertsen & Øystein Bruserud

Authors
  1. Bjørn Tore Gjertsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Øystein Bruserud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Øystein Bruserud.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gjertsen, B.T., Bruserud, Ø. How should clinical data be included in experimental studies of cancer immunology?. Cancer Immunol Immunother 53, 677–680 (2004). https://doi.org/10.1007/s00262-004-0515-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-004-0515-y

Keywords

Search

Navigation